ReviewJournal of hematology & oncology2017
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
Review in Journal of hematology & oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 94 citations in OpenAlex.
- Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.Cancer science · 2020Trial
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.Journal of hematology & oncology · 2018Trial
- CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality.Journal of hematology & oncology · 2026Review
- SNX10 regulates the proliferation, apoptosis and cell cycle of acute B lymphoblastic leukemia cells via the PI3K/Akt signaling pathway.Oncology reports · 2025Article
- Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database.International journal of surgery (London, England) · 2025Article
- Immunotherapy in chronic lymphocytic leukemia: advances and challenges.Experimental hematology & oncology · 2025Review
- Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.Cancer · 2024Review
- Comprehensive pan-cancer analysis reveals that C5orf34 regulates the proliferation and mortality of lung cancer.Functional & integrative genomics · 2024Article
- Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.Investigational new drugs · 2024Article
- Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review.Frontiers in oncology · 2024Article
- A breast cancer classification and immune landscape analysis based on cancer stem-cell-related risk panel.NPJ precision oncology · 2023Article
- Identification of potential diagnostic biomarkers of atherosclerosis based on bioinformatics strategy.BMC medical genomics · 2023Article
- Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.Frontiers in immunology · 2023Review
- Precision Medicine in Therapy of Non-solid Cancer.Handbook of experimental pharmacology · 2023Review
- Cell membrane coated-nanoparticles for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2022Review
- Review
- In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.The Lancet. Haematology · 2022Article
- A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse.Microorganisms · 2022Review
- Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report.Frontiers in oncology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as CD19, CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results. Among the immunotherapeutic methods, naked monoclonal antibodies (mAbs), antibody-drug conjugate (ADC), bispecific T cell engager (BiTE), and chimeric antigen receptor (CAR) T cells are the main types. In this review, we will examine the emerging preclinical and clinical development on (1) anti-CD20 naked mAbs rituximab, ofatumumab, and obinutuzumab; (2) anti-CD19 ADCs SAR3419 and SGN-CD19A and anti-CD19 BiTE blinatumomab; (3) anti-CD22 naked mAb epratuzumab and anti-CD22 ADC inotuzumab ozogamicin; (4) anti-CD52 naked mAb alemtuzumab; and (5) anti-CD19 CAR T cells. We will discuss their efficacy, adverse effects, as well as future development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.